Addback of Donor CD45RA Depleted Cells

CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/​CD19 Depleted HSCT

What will happen during the trial?

The risk of severe graft versus host disease (GVHD) is increased with the use of unrelated and partially matched related donors. T cell depletion reduces the risk of severe GVHD, but immune reconstitution is delayed. Important memory T cells that may protect patients from fungal and viral infections are also removed in the T depletion process. CD45RA depletion has been studied both as a single step to reduce the risk of GVHD, and also, in conjunction with αβTCR depleted hematopoietic stem cell grafts to accelerate immune reconstitution. This is a single institutional pilot trial of this T cell depletion technique. Patients with acute leukemias at high risk for relapse are eligible to participate. Patients will be given CD45RA depleted donor peripheral stem cells (PSCs) following T depleted hematopoietic stem cell transplant (HSCT). A short course of GVHD prophylaxis will be used after CD45RA depletion.

More Information

Trial Status
Accepting patients
Enrollment
50 patients (estimated)
Sponsors
Children's Hospital of Philadelphia
Tags
Donor Lymphocyte Infusion (DLI), Chemotherapy, Allogeneic Stem Cell Transplant, T Cell, Post-Allogeneic Stem Cell Transplant, Radiation Therapy
Trial Type
Supportive
Last Update
SparkCures ID
1653
NCT Identifier
NCT03810196

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.